Preclinical studies in androgen-sensitive prostate cancer xenografts demonstrated that ADT results in a significant of VEGF levels and subsequent androgen replacement led to upregulation of VEGF expression [60]. This evidence concerns the gene VEGFA and prostate carcinoma.